J Pharmacol Exp Ther 238:54-61
Un equipo internacional de investigadores de China, Canad y varios pases europeos publica en The British Medical Journal (BMJ) una revisin sistemtica y un metaanlisis en red que rene los resultados de 262 ensayos clnicos aleatorizados con cerca de 100.000 participantes y compara 19 tratamientos farmacolgicos para la obesidad, tanto ya comercializados como en desarrollo con seguimientos de entre 12 y 172 semanas
In 2021, the FDA also required an updated warning about the risk of hypoglycemia, including severe hypoglycemia, in patients using Byetta in combination with insulin or other drugs that increase insulin levels
The Science Behind Semaglutide Semaglutide is an FDA-approved medication under the GLP-1 receptor agonist category, and it's designed for adults managing obesity or those with related health conditions
GLP-1 receptor agonists, such as liraglutide, exenatide, and semaglutide, originally developed for type 2 diabetes (T2DM) management, show promise in improving psoriasis symptoms by reducing inflammation and addressing metabolic issues
